Complicated proliferative diabetic retinopathy, treatment options by Goțonoaga, Cătălina
COMPLICATED PROLIFERATIVE DIABETIC RETINOPATHY, TREATMENT OPTIONS.
Author: Goțonoaga Cătălina
Scientific adviser: Corduneanu Angela, PhD, assoc. prof. Chair of Ophtalmology
Introduction: Diabetes mellitus is one of the
most widespread metabolic pathology, caused
by glucose excess, (Fig. 1) affecting about 463
million of adults worldwide. Diabetic
retinopathy (DR) is one of the most serious
complications, leading to progressive decline
and loss of vision. A recent meta-analysis pol
(1990-2020) reported that in 2015, 2.6 million
people were visually impaired due to DR, a
figure projected to rise to 3.2 million in 2020,
with a global overall prevalence of 34.6% for
any DR.
Purpose: To study contemporary methods of
treatment and prevention of a complicated
diabetic retinopathy.
Material and methods: Scientific articles
published in international specialized journals
during the period of 2016 -2020.











Conclusions: The pharmacological products used in time can prevent the
occurrence of complicated proliferative diabetic retinopathy. For direct
treatment of complications surgical methods are more effective, these are:
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•Improving blood glucose control with oral antidiabetic
drugs and insulin (Fig.3), maintaining HbA1c levels 
under 7.5%. Monitor blood pressure using 
antihypertensive drugs, as well as correction of 




•Intraocular injections with anti-VEGF agents are used to prevent 
neovascularization by inhibiting the endothelial growth factor 
responsible for cell proliferation in blood vessels. (Fig.2)
•Panretinal photocoagulation: using Argon, Krypton and 
micropulse diode laser technologies. 
•Vitrectomy also a surgical procedure used for the vitreous 
hemorrhage of 1–3 months duration or longer. It is used for scar 






•Adose reductase inhibitor: The mechanism of action is to reduce 
the flow of glucose through the polyol pathway leading to 
inhibition of tissue accumulation of sorbitol and fructose, thus 
preventing the reduction of redox potentials. This therapy has 
been successfully tested on diabetic mice and dogs, expecting 
more in-depth studies on humans. 
III. Future 
therapies:
